SCHEMBL4045808

SCHEMBL4045808

CC(C)CC(NC(=O)Oc1ccc(-c2ccccc2)s1)C(=O)N1CCC2C1C(=O)CN2C(=O)c1ccc[n+]([O-])c1

nearest known ligand 0.54

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
CTSK P43235 16/20 0.54
CTSS P25774 6/20 0.41
CTSL P07711 6/20 0.35
CTSB P07858 2/20 0.35
HTRA1 Q92743 1/20 0.34
CCR1 P32246 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4050196 0.93 CTSK (0.56) CTSKCTSSCTSLCTSBHTRA1
SCHEMBL4043745 0.92 CTSK (0.63) CTSKCTSSCTSLCTSBCCR1
SCHEMBL4039365 0.89 CTSK (0.59) CTSKCTSSCTSLCTSBCCR1
SCHEMBL4043639 0.88 CTSK (0.49) CTSKCTSSCTSLCTSB
SCHEMBL4045086 0.87 CTSK (0.42) CTSKCTSSCTSLCTSBHTRA1
SCHEMBL4046048 0.87 CTSK (0.57) CTSKCTSSCTSLCTSB
SCHEMBL4044454 0.86 CTSK (0.55) CTSKCTSSCTSLCTSB
SCHEMBL4049421 0.86 CTSK (0.54) CTSKCTSSCTSLCTSB
SCHEMBL4045362 0.86 CTSK (0.54) CTSKCTSSCTSLCTSB
SCHEMBL4049584 0.85 CTSK (0.51) CTSKCTSSCTSLCTSB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1546150-B1 PYRROLE DERIVATIVES AS INHIBITORS OF CYTEINE PROTEASES AMURA THERAPEUTICS LTD (GB) 2009-03-04 EP claimed
US-20060100431-A1 Biologically active compounds AMURA THERAPEUTICS LIMITED (GB) 2006-05-11 US claimed
EP-1546150-B1 PYRROLE DERIVATIVES AS INHIBITORS OF CYTEINE PROTEASES AMURA THERAPEUTICS LTD (GB) 2009-03-04 EP disclosed
US-20060100431-A1 Biologically active compounds AMURA THERAPEUTICS LIMITED (GB) 2006-05-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060100431-A1 Biologically active compounds SOST, CTSK, CTSS CTSK 2/4885CTSS 3/4885CTSL 57/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.